Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe this will begin to move a little faster now!
Got in today! Looking for good things to come!
I think so!
Good to see the ask slaps at eod!!
Filings out!
3’s coming
Looking good! Hold those shares!
Looking strong. Hold those shares
Going nowhere but up!
Volume should be good today!
Trading like a champ!
Hold your shares.
Bid and ask size upside down! Hold those shares!
Looking good! 6’s next
Twitter.
@ez_vending
Correct.
Filings are expected soon. Closer to becoming current.
$GTEH VP of Sales Harold was a guest at Golds Gym to do a presentation on Functional Foods and specifically SINFIT Nutrition. It was an honor for us to be invited. #sinfitnutrition #functionalfoods #Goldsgym #takeover pic.twitter.com/KiMXL50aFk
— Sinfit Nutrition (@sinfitnutrition) December 15, 2020
$GTEH SINFIT Nutrition is going to be at the Olympia this weekend. We are the main sponsors for the wheelchair division. We will@be on stage handing out awards. #sinfinutrition #takeover #functionalfood #realproduct #realcompamy pic.twitter.com/T6oCnj0Ohx
— Sinfit Nutrition (@sinfitnutrition) December 15, 2020
Referring to nickel and dime range.
6:18a ET 12/15/2020 - Globe Newswire
KRONOS ADVANCED TECHNOLOGIES INC APPLIES TO UPLIST TO THE OTC MARKET'S QUALITY BOARD
Mentioned: KNOS OTCM
Los Angeles, CA, December 15, 2020 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC., (OTC MARKETS: KNOS) ("KNOS" or the "Company"), a revenue-generating, product development and production company that has significantly changed the way air is moved, filtered and sterilized announced today that the Company applied for a tier upgrade to the OTCQB(R) Venture Markets.
OTCQB(R) Venture Market is operated by the OTC Markets Group, Inc. and is designed for early-stage and developing U.S. and international companies, offering companies the opportunity to build visibility, expand liquidity and diversify their shareholder base. To be eligible for quotation on the OTCQB(R), companies must meet certain SEC or alternative reporting requirements, maintain annual financials audited by a PCAOB qualified accountant, post initial and annual verifications and management certifications. Companies must also meet a minimum bid price test and other conditions. The OTCQB(R) is recognized by the Securities and Exchange Commission (SEC) as an "established public market" for determining the public market price, allowing broker-dealers and their customers to more easily trade stocks and invest in a variety of OTCQB traded companies.
"Uplisting to the OTCQB(R) Venture Market will provide us with greater recognition amongst the investment community as well as our shareholders as we continue to execute on our business plan and reach expansion milestones," said Michael Rubinov, President of Kronos. "A listing on the OTCQB(R) Venture Market significantly broadens the exposure to potential investors. Historically, companies that have uplisted to the OTCQB(R) tier have experienced increased investor awareness and visibility of their common stock as well as an increase in shareholder value. Kronos' management is also in the process of preparing an S-1 registration statement in order to become an SEC reporting public Company allowing us to increase transparency and improve credibility with shareholders more greatly. This way, Kronos will further increase (beyond OTCQB) its exposure to institutional investors and attract further direct investment through the open markets and therefore meet another important (beyond audits) qualification for uplisting to a more prestigious exchange when certain additional hallmarks are met."
Exactly why I just got in today.
8k filed yesterday after close.
Volume picking up!
Could be due to the broker you use. Example: Ameritrade allows larger block OTC orders (over 1M shares) for a $6.95 fee per trade. Some brokers offer free trades, but limit the quantities.
Good activity! Thank you!
One of the high volume movers of the day
Multiple Sinfit products selling on Amazon with great reviews “Amazons Choice”... Just hold tight.
West Palm Beach, FL, Nov. 25, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --Ethema Health Corporation (OTCPINK: GRST) (“Ethema” “GRST” or the “Company”), is pleased to announce several very positive developments for Evernia Health Center LLC dba ARIA (“ARIA”). On November 24, 2020 ARIA received its LegitScript Certification. LegitScript is the credentialling body that provides certifications, without which companies in the Substance Use Disorder (SUD) industry cannot use pay per click (“PPC”) advertising on Google. ARIA has programmed a large portion of its marketing spend on Google PPC advertising. ARIA engaged the services of Dreamscape Marketing in June 2020 to build its website, manage the website SEO and manage the PPC advertising spend. DreamScape Marketing is a specialist marketing company in the SUD industry and is a very large and successful marketing company serving the SUD industry.
The Company is very pleased with the progress that ARIA has made in the first month of operations and now with the ability to expand the marketing program for the new treatment center, it expects to see rapid growth of the business. The Company is forecasting very strong demand in 2021 for SUD treatment services due to the traumatic effect that the Pandemic has had on so many people and the increases it has caused in substance use.
ARIA will be completing its licensing process in the month of December when the Department of Children and Family services conducts its audit that will change ARIA’s license status from probationary to full license. The audit is normally done within the first 90 days after receiving a new license. This is significant, as the full license status will allow ARIA to complete the process of getting in-network with several large insurers. ARIA has made significant progress on this front and ARIA recently received a provider number from Blue Cross, which it received much sooner than expected, allowing ARIA to admit Blue Cross insured clients.
About Ethema Health Corporation
Ethema Health Corporation (OTCPINK: GRST) operates in the behavioral healthcare space specifically in the treatment of substance use disorders. Ethema developed a unique style of treatment over the last eight years and has had much success with in-patient treatment for adults. Ethema will continue to develop world class programs and techniques for North America. For more information you can visit our website at www.ethemahealth.com .
NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has signed a licensing agreement with Restorsea , a leading medical grade skincare technology platform.
Conversion Labs plans to use Restorsea’s intellectual property and proprietary formulations to create a best-in-class clinical-grade over-the-counter skincare line that will be marketed under the new Nava MD™ brand. The company plans to launch Nava MD in the first quarter of 2021.
Restorsea’s clinically proven skincare technology platform was the result of more than $50 million invested in R&D and intellectual property development over the last several years, and has received 35 patents along with broad industry acclaim .
Restorsea’s breakthrough clinical results have also been published in the peer-reviewed Journal of Drugs in D ermatology and Journal of Cli n ical and Aesthetic Dermatology . Nava MD will be the first and presently the only direct-to-consumer product line outside of Restorsea to offer this advanced skincare technology.
Nava MD will be positioned as an online skincare and teleHealth brand that will offer teledermatology services to patients in all 50 states. Teledermatology represents one of the fastest growing segments of the U.S. telehealth market. According to Fortune Business Insights , the teledermatology market is expected to grow at a 24.3% CAGR to $44.9 billion by 2027.
“As with traditional brick and mortar dermatology, medical-grade over-the-counter products are an integral part of treating aging, dryness, acne, and other prevalent skin conditions,” stated Justin Schreiber, CEO of Conversion Labs. “Given the clinical results and industry acclaim, the Restorsea technology is in a league of its own. Incorporating it into our new direct-to-consumer teledermatology offering represents a major competitive advantage for Conversion Labs.”
According to Restorsea founder and CEO, Patti Pao, who has launched more than 400 products for top brands like Avon, Elizabeth Arden, and Guerlain: “We are thrilled to partner with Conversion Labs for this historic launch of their Nava MD line featuring our advanced skincare technologies. We’re excited that it includes our natural proprietary biocatalyst exfoliator, Aquabeautine XL®.”
Aquabeautine XL® is the only known natural substance that cleaves only dead skin cells, leaving living, healthy cells untouched. It makes skin look radiant, smooth, and even in tone and texture, and without the redness, irritation or thinning skin typically associated with the use of traditional exfoliators.
“Our licensing of the Restorsea technology platform demonstrates our commitment to creating patented and proprietary telemedicine product lines that address large and underserved markets,” commented Conversion Labs CTO, Stefan Galluppi. “The more than $50 million invested in Restorsea’s intellectual property and product development came from a handful of the most sophisticated investors in the U.S. This level of investment is almost unprecedented in the skin care and dermatology world, and it is reflected in the quality and effectiveness of the Restorsea technology. We expect this to translate into great results for our patients and strong customer retention for Conversion Labs.”
The company’s new cloud-based telemedicine platform, Veritas MD ™, is expected to play a large role in the successful rollout of Nava MD, according to Galluppi: “Given the unique capabilities of Veritas MD, we are able to develop, introduce and deliver new products faster and more efficiently than ever before. Veritas MD not only provides incredible operational leverage by supporting greater scale at lower cost, but more importantly, its well-designed video-powered, mobile interface enhances the overall user experience for both patients and doctors.”
According to Forrester Research , telehealth has “shifted into hyper-drive,” with virtual health care consultations on pace to top 1 billion by year end. The overall telemedicine market is expected to grow at 19.3% CAGR, reaching $175.5 billion by 2026.
The teledermatology market has been seeing steady growth over the last few years; however, accelerated investments in healthcare technology and the recent pandemic have worked together to set the industry on a higher growth trajectory. Prior to the pandemic, teledermatology was viewed as generally suitable for most populations, but now it is considered an “absolute necessity” given the greater safety and cost-savings it provides.
Nava MD is Conversion Labs’ fourth telemedicine brand. The success of these brands has been demonstrated by the company’s accelerating growth, with its annualized revenue run-rate currently triple over all of last year at more than $46.8 million.
Conversion Labs’ annual recurring revenue (ARR) from subscriptions increased by $2.2 million or 13% to $19.3 million in September 2020 compared to August. ARR increased by $15.8 million or 458% versus September 2019.
Translation- big run coming.
Los Angeles, CA, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Los Angeles, CA, September 30, 2020 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC., (OTC MARKETS: KNOS) ("KNOS" or the "Company"), a revenue-generating, product development and production company that has significantly changed the way air is moved, filtered and sterilized today announced that Amway’s former COO, William “Bill” Nicholson has agreed to provide valuable strategic advisory services to management. Mr. Nicholson will leverage his skills and expertise to provide guidance and direction to the company’s executive team through its continued growth and development as an air purification and disinfection industry leader. He brings with him years of experience with a strong background in the management of business operations, growth and profitability.
William Nicholson, brought aboard through our current board of advisors Kevin Harrington and Steve Mandell, previously served as Appointments Secretary to President Gerald R. Ford and was a key player at the Amway headquarters beginning in 1984. He oversaw the introduction of many of AMWAY’s then new products and services. William Nicholson commenced an eight-year stint as COO of Amway Corporation during which time he oversaw revenues grow from under $1 billion to over $6 billion up to 1992. Since 1992, Mr. Nicholson continued his entrepreneurial successes in a variety of industries.
The appointment of Bill Nicholson builds on the company’s broader growth strategy, following the completion of the acquisition of the electronics manufacturing facility planned before the end of the year.
“Kronos has an outstanding team and Mr. Nicholson’s role represents significant progress for the company as they evolve from a small technology company into a truly national leader of indoor air quality management solutions, services and unique patented air purification products,” says Kevin Harrington, Adviser to Kronos. As a world class business leader, Mr. Nicholson is one of the finest individuals to add to the Kronos team to further scale the Kronos Products on a global basis,” says Steve Mandell, Advisor to Kronos.
“I am familiar with Kronos technology having closely followed the Company for many years as a witness to the rapid progress the company has made in revolutionizing the air purification industry by eliminating the need for the half century old HERA filtration technology. That technology became obsolete when utilizing Kronos’ innovative cold plasma, filterless technology,” said Mr. Nicholson. “This is perfect time for Kronos and I am very excited to work with their incredible management adding my decades of air purification sales and marketing experience to the team.”
As Covid-19 disrupts global supply chains, American manufacturers are seeking out ways to restructure national supply chains and search for new manufacturing practices.
Harvard Business review recently reported that Companies in the United States, Canada, Europe, and Australia have been hit with supply chain shocks as the flow of materials from China was disrupted by the pandemic. CEOs are confidentially asking their supply chain teams to develop additional sources that are completely independent of China. In addition, in the United States there is pressure from employees who are wary of traveling to China, from customers who are concerned (rationally or not) about the safety of foods and other items from that country, from investors who worry greatly about over-dependence on any one country, and increasingly from politicians as well as State Department leaders who want companies to rapidly decouple from China.
In this regard, Mr. Nicholson brings extensive experience in both executive leadership and the scaling of global operations to the KNOS Board of Advisors.
Los Angeles, CA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Los Angeles, CA, September 25, 2020 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC., (OTC MARKETS: KNOS) ("KNOS" or the "Company"), a revenue-generating, product development and production company that has significantly changed the way air is moved, filtered and sterilized, today announced its integration with SPS Commerce, Inc., a provider of advanced, cloud-based retail supply chain management solutions. Kronos' e-commerce customers can now utilize powerful EDI and retail supply chain automation solutions.
SPS Commerce provides its customers with end-to-end electronic data interchange (EDI) integrations, order management and analytics solutions. SPS Commerce helps retailers add EDI to their supply chain operations and helps companies scale via integrations with other business systems, including Shopify integration. The integration between Kronos e-commerce and SPS Commerce allows our business customers to be EDI compliant. By sharing order details and real-time status between all of Kronos retail and online partners, all parties can reduce order processing time and ship faster and more efficiently.
"We're excited to integrate with SPS Commerce," said Michael Rubinov, President and Business Development Officer. "The combination of SPS Commerce and our online stores provides our customers with an enterprise-grade solution to manage all aspects of their e-commerce business with us. Consumers and business customers are increasingly choosing e-commerce as their primary shopping choice. Fulfilling these online orders requires the ability to ship quickly and profitably. This integration will help our resellers and business partners to streamline the order fulfillment process and minimize COVID-19 caused global supply chain disruptions."
About SPS Commerce
SPS Commerce is the world's leading retail network, connecting trading partners worldwide to optimize supply chain operations for all retail partners. They support data-driven partnerships with innovative cloud technology, customer-obsessed service, and accessible experts so their customers can focus on what they do best. To date, more than 90,000 companies in retail, distribution, grocery, and e-commerce have chosen SPS as their retail network.
About Kronos Advanced Technologies, Inc.
Kronos Advanced Technologies, Inc. began operations in 2002 as a product development company that invented and significantly changed the way air is moved, filtered, and sterilized. Historically, Kronos has focused on developing, marketing, and selling the Company's proprietary air movement and purification technology. Serving the Indoor Air Quality (IAQ) market, Kronos technology uses state-of-the-art high voltage patented processes without traditional porous HEPA filters. Kronos-based products move air efficiently , filter, sterilize and purify the air, while dramatically reducing energy consumption to half of a 60-watt light bulb. Kronos devices can be variable in shape or size, and, therefore, have the potential to be scaled-down for air purification in cars or scaled-up in size for industrial and hazardous gas destruction. The technology is currently being implemented in multiple standalone products for businesses, homes, and vehicles of all types -to move, sterilize and filter air, including removing allergens down to 14.6 nanometers, passing through our patented technology -replacing expensive outdated passive HEPA and other filtration type systems. There are broad ranges of additional markets for standalone and embedded Kronos CORE technology-based devices. Examples of immediately addressable markets include schools, universities, Healthcare facilities, operating rooms, manufacturing clean rooms, and the cabins of automobiles and commercial aircraft.
Recently the Company filed for a provisional patent involving an innovative protective face mask with antimicrobial and anti-cellphone radiation protection features. The Company is planning to file additional patents to improve its existing technology as well as enter into new market segments but will continue to market air purifiers and other consumer products. The Company is an exclusive distributor and licensee of the latest generation of air purifiers based on the Company's CORE technologies. The Company markets its products as Airdog® and KRONOS® brands. Company offices are located in Los Angeles, California.
TORONTO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its psychedelics therapeutics programs specifically as it relates to the Company’s oral thin-film delivery system and clinical studies with psilocybin at the University of Wisconsin-Madison.
“We are expanding our product pipeline with a focus on psychedelic therapeutics incorporating our novel oral thin-film delivery technology with psilocybin, in which we have prototypes developed and we will move towards clinical studies with the University of Wisconsin-Madison along with other key industry partners,” said Michael Frank, CEO of Revive. “In addition, we are advancing our Phase I clinical study to evaluate the safety and feasibility of psilocybin in adults with Methamphetamine Use Disorder. Our initiatives in product development and clinical studies gives us a leading position in the psychedelic space.”
Psilocybin Oral Thin-film Product
Under its sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison, the Company is developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity. The Company has received its final set of prototypes and is preparing to scale for manufacturing for future clinical studies involving psilocybin and other psychedelic-derived medicines. There are a number of advantages and benefits of an orally dissolvable psilocybin thin film such as the rapid dissolving and onset of action to the bloodstream, the ease and convenience for patients to administer without the need of water, chewing or swallowing, the potential of improved therapeutic outcomes and efficacy for underserved diseases and disorders including the flexibility to create accurate dosing and tasteful options.
The Company’s delivery technology is a natural, non-toxic, biodegradable and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties. The delivery technology has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.
Clinical Study of Psilocybin in the Treatment of Methamphetamine Use Disorder
The Company recently announced that it has entered into a Clinical Trial Agreement with the Board of Regents of the University of Wisconsin System to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.” The Phase I study Principal Investigator is Dr. Christopher R. Nicholas, Ph.D., Assistant Professor of Program for Research Outreach Therapeutics and Education in the Addictions in the Department of Family Medicine and Community Health at University of Wisconsin School of Medicine and Public Health. The clinical study will be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health, and School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin. The Company will have exclusive access to key intellectual property from this study.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com .
NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has completed its previously announced equity investment by a select group of private investors and family offices, including investors David Blitzer and Wes Edens, for $3.5 million. Conversion Labs also submitted this week its application to list the company’s common stock on the Nasdaq Capital Market®.
“In addition to the tremendous affirmation of our business strategy and growth prospects these investors represent, their capital contribution advances us toward satisfying the listing requirements for Nasdaq,” commented Conversion Labs CEO, Justin Schreiber. “As the world’s top exchange for emerging growth stocks, we expect a Nasdaq listing to increase our corporate visibility and broaden awareness of our success in the financial community.”
“We anticipate a Nasdaq listing will open the door to a larger pool of investors, particularly institutional and retail, and help drive greater shareholder value,” continued Schreiber. “These multiple benefits will be timely, as we expect to soon announce a number of new telemedicine products that will leverage our record customer growth and the vast market opportunities that continue to emerge in teleHealth.”
Over the last year, Conversion Labs has made great strides in strengthening its operational and financial performance which have positioned it for future growth and profitability. The company’s new cloud-based, video-powered telemedicine platform, Veritas MD, has been designed to support the continued rapid scale up and market expansion of the company’s telehealth brands, while providing easier, more convenient and affordable access for patients seeking personalized treatment by board-certified physicians.
The company annualized revenue run-rate recently exceeded $44.0 million compared to $12.5 million for all of 2019—a more than three-fold increase. The growth in revenue has been largely driven by the company’s increasingly popular proprietary brands and formulas that include Rex MD and Shapiro MD.
Subscriptions to these products increased the company’s annual recurring revenue (ARR) to $17.2 million by the end of August, which was up by $14.0 million or 437% compared to August of last year. The month-to-month increase from July had jumped by a record $2.4 million.
“Our accelerating performance with subscription revenue reflects how we are attracting loyal customers who value the convenience and security that our telehealth platform provides,” added Schreiber. “As we launch additional telemedicine offerings and products, we expect our growth to continue its upward trajectory as improving economies of scale drive greater margin expansion.”
In addition to delivering highly-effective products and services, the company has been benefiting from the growing adoption of telemedicine across the health care industry. According to Forrester Research, telehealth has “shifted into hyper-drive,” with virtual health care visits on pace to top 1 billion by year end. The telemedicine market is expected to grow at 19.3% CAGR, reaching $175 billion by 2026.
Acceptance for listing the company’s shares is subject to approval based on several factors, including satisfaction of minimum listing requirements for the Nasdaq Capital Market. The company intends to satisfy all of the applicable listing requirements; however, there is no assurance that its application will be approved. During the Nasdaq review process, the company’s common stock will continue to trade in the U.S. on The OTC Markets under its current symbol, CVLB.
About Nasdaq
Nasdaq, Inc. (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Its diverse offering of data, analytics, Computer and services enables clients to optimize and execute their business vision with confidence. The Nasdaq Stock Market is a trusted pillar of capital markets and innovation, providing U.S. equity markets liquidity, resiliency and transparency that propel investment ideas to fruition. For more about Nasdaq, go to www.nasdaq.com.
About Conversion Labs
Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company’s brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.
Annual Recurring Revenue (ARR)
Conversion Labs calculates annual recurring revenue (ARR) by multiplying by 12 the monthly sum of revenue attributed exclusively to automatic subscription sales from customers that are engaged in the company’s rebill structure for the brands of Shapiro MD, Rex MD and PDFSimpli. In the company’s calculation of ARR, it does not consider sales from customers that repurchase its products themselves in the company’s checkout pages, Amazon Marketplace or through assistance of the company’s customer service representatives, since those sales have a marginal advertising/marketing expense associated with the respective sale. The company also does not consider the revenue attributed to the initial purchase upon acquisition of the respective customer.
Important Cautions Regarding Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Trademarks are the property of their respective owners.
Company Contact
Conversion Labs
Juan Manuel Piñeiro Dagnery
CFO
Email Contact
Media and Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
SANDUSKY, Ohio, Sept. 14, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced an interview of CEO James C. DiPrima on MoneyTV with Donald Baillargeon scheduled for release this Friday, September 18, 2020. DiPrima will discuss the company's latest CBD bio pharma developments in addition to fielding questions on the Goldman Small Cap Analyst Research Update published today with a $0.015 PPS 12-Month Target.
Last Mr. DiPrima was on MoneyTV he discussed PAOG's partnership with a Contract Research Organization (CRO) and a formal agreement in the works to advance an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for PAOG's RespRx as a COPD treatment.
The COPD treatment, RespRx, is derived from a patented Cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
MoneyTV with Donald Baillargeon is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures. MoneyTV is seen in over 200 million TV households in more than 75 countries.
The MoneyTV Interview will be available at www.moneytv.net and will be syndicated across multiple channels and platforms.
www.paogroupinc.com
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
SOURCE PAO Group, Inc.
Looking good!
It will happen.
Sounds like a plan. Let’s only hope.